Is Zura Bio Ltd (ZURA) Halal?

NASDAQ Healthcare United States $563M
✓ HALAL
Confidence: 67/100
Zura Bio Ltd (ZURA) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 0.0% against the AAOIFI threshold of 30%, Zura Bio Ltd comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Biotechnology), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.0%
/ 30%
26.7%
/ 30%
0.0%
/ 30%
N/A ✓ HALAL
DJIM 0.0%
/ 33%
26.7%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
MSCI 0.0%
/ 33%
98.3%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 0.0%
/ 33%
26.7%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
FTSE 0.0%
/ 33%
98.3%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-1.06
P/B Ratio
4.3
EV/EBITDA
-6.0
EV: $453M
Revenue
$0
Beta
0.2
Low volatility
Current Ratio
9.1

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -52.5%
Return on Assets (ROA) -32.0%

Cash Flow & Balance Sheet

Operating Cash Flow-$28M
Free Cash Flow-$33M
Current Ratio9.1
Total Assets$180M

Price & Trading

Last Close$6.04
50-Day MA$6.21
200-Day MA$3.70
Avg Volume687K
Beta0.2
52-Week Range
$0.97
$7.44

About Zura Bio Ltd (ZURA)

CEO
Dr. Sandeep C. Kulkarni M.D.
Employees
40
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$563M
Currency
USD

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Zura Bio Ltd (ZURA) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Zura Bio Ltd is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Zura Bio Ltd's debt ratio?

Zura Bio Ltd's debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.

What are Zura Bio Ltd's key financial metrics?

Zura Bio Ltd has a market capitalization of $563M. Return on equity stands at -52.5%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.